0 142

Cited 6 times in

A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer

Authors
 Kyong Joo Lee  ;  Seung Woo Yi  ;  Jihye Cha  ;  Jinsil Seong  ;  Seungmin Bang  ;  Si Young Song  ;  Hee Man Kim  ;  Seung Woo Park 
Citation
 CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.78(4) : 841-846, 2016 
Journal Title
 CANCER CHEMOTHERAPY AND PHARMACOLOGY 
ISSN
 0344-5704 
Issue Date
2016
MeSH
Adult ; Aged ; Antimetabolites, Antineoplastic/administration & dosage ; Antineoplastic Agents/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Biliary Tract Neoplasms/diagnostic imaging ; Biliary Tract Neoplasms/drug therapy* ; Biliary Tract Neoplasms/radiotherapy* ; Chemoradiotherapy/adverse effects ; Chemoradiotherapy/methods* ; Cholangiocarcinoma/drug therapy ; Cholangiocarcinoma/radiotherapy ; Cisplatin/administration & dosage ; Combined Modality Therapy ; Common Bile Duct Neoplasms/drug therapy ; Common Bile Duct Neoplasms/radiotherapy ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Disease-Free Survival ; Female ; Gallbladder Neoplasms/drug therapy ; Gallbladder Neoplasms/radiotherapy ; Humans ; Klatskin Tumor/drug therapy ; Klatskin Tumor/radiotherapy ; Male ; Middle Aged ; Pilot Projects ; Tomography, X-Ray Computed ; Treatment Outcome
Keywords
Biliary tract cancer ; Chemoradiotherapy ; Cisplatin ; Gemcitabine ; Survival
Abstract
PURPOSE: Combination chemotherapy with gemcitabine and cisplatin is a standard treatment for patients with advanced biliary tract cancer. This study aimed to evaluate the efficacy and safety of gemcitabine- and cisplatin-based concurrent chemoradiotherapy in patients with unresectable biliary tract cancer. METHODS: Patients with pathologically proven, unresectable, non-metastatic biliary tract cancer were enrolled. Gemcitabine was administered intravenously at a dose of 1000 mg/m(2) on days 1, 8, and 15. Cisplatin was administered intravenously at a dose of 70 mg/m(2) on day 1. All the patients underwent concurrent radiotherapy with 45 Gy in 1.8-Gy daily fractions. After treatment completion, tumor response was evaluated by using computed tomography. RESULTS: Eighteen patients were enrolled between June 2007 and October 2011. Their median age was 61 years (range, 38-72 years). Eight patients (44.5 %) were diagnosed with gallbladder cancer, six (33.3 %) with Klatskin's tumor, and four (22.2 %) with distal common bile duct cancer. After treatment completion, partial response was achieved in five patients (27.8 %) and stable disease in 13 patients (72.2 %). The overall response rate was 27.8 %, and the disease stabilization rate was 100 %. No grade 4 adverse events or treatment-related deaths occurred. The most common grade 3 adverse events were thrombocytopenia (33.3 %) and anemia (11.1 %). The median progression-free and overall survival times were 6.8 months (range, 4.5-19.8 months) and 9.6 months (5.4-30.4 months), respectively. CONCLUSIONS: This study shows that gemcitabine- and cisplatin-based concurrent chemoradiotherapy is feasible and tolerable in patients with unresectable and non-metastatic biliary tract cancer.
Full Text
https://link.springer.com/article/10.1007%2Fs00280-016-3143-2
DOI
10.1007/s00280-016-3143-2
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Park, Seung Woo(박승우) ORCID logo https://orcid.org/0000-0001-8230-964X
Bang, Seungmin(방승민) ORCID logo https://orcid.org/0000-0001-5209-8351
Seong, Jin Sil(성진실) ORCID logo https://orcid.org/0000-0003-1794-5951
Song, Si Young(송시영) ORCID logo https://orcid.org/0000-0002-1417-4314
Yi, Seung Woo(이승우) ORCID logo https://orcid.org/0000-0002-5929-9444
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/152268
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse